An Efficacy and Safety Study of Epoetin Alfa (PROCRIT) Initiated at 40,000 Units Every Week Versus 80,000 Units Every Two Weeks in Anemic Patients With Cancer Receiving Chemotherapy.
Clinical trial NCT00210834 · COMPLETED
Trial details
- NCT number
- NCT00210834
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2004-05-01
- Enrollment
- 310
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.